Urokinase-type plasminogen activator system and breast cancer (Review)

Oncology Reports

Volumn 14, Issue 1, 2005, Pages 105-112

  Han, Bo ^a   Nakamura, Misa ^a   Mori, Ichiro ^a   Nakamura, Yasushi ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Metastasis; Prognosis; Urokinase type plasminogen activator

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UROKINASE;

BIOLOGICAL MODEL; BREAST TUMOR; CANCER INVASION; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 24644441893     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. McPherson K, Steel CM and Dixon JM: ABC of breast diseases. Breast cancer epidemiology, risk factors and genetics. Br Med J 321: 624-628, 2000.
2. International Agency for Research on Cancer. Cancer incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. IARC Press, Lyon, 2001.
3. Boyd D: Invasion and metastasis. Cancer Metastasis Rev 15: 77-89, 1996.
4. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
5. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
6. Rabbani Sa and Xing RHM: Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies (review). Int J Oncol 12: 911-920, 1998.
7. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H and Schmitt M: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 13: 893-906, 1998. (Pubitemid 28506055)
8. Stephens RW, Brunner N, Janicke F and Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99-111, 1998. (Pubitemid 29056088)
9. Duffy MJ: Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem48: 1194-1197, 2002.
10. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993. (Pubitemid 23062819)
11. Look MP, van Putten WL, Duffy MJ, et al: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128, 2002. (Pubitemid 34121291)
12. Ossowski L, Russo-Payne H and Wilson EL: Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51: 274-281, 1991.
13. Guo Y, Higazi AA, Arakelian A, et al: A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400-1410, 2000. (Pubitemid 30439749)
14. Rabbani SA and Gladu J: Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62: 2390-2397, 2002. (Pubitemid 34411723)
15. Montuori N, Rossi G and Ragno P: Post-transcriptional regulation of gene expression in the plasminogen activation system. Biol Chem 383: 47-53, 2002. (Pubitemid 34224027)
16. Blasi F, Vassalli JD and Dano K: Urokinase-type plasminogen activator: proezyme, receptors and inhibitors. J Cell Biol 104: 801-804, 1987. (Pubitemid 17068652)
17. Dano K, Andreasen PA, Grondal-Hansen J, Kristensen P, et al: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
18. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M and Nagamine Y: The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56: 104-132, 1999. (Pubitemid 29471930)
19. Vassalli JD, Sappino AP and Belin D: The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072, 1991.
20. Ellis V, Scully MF and Kakkar VV: Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264: 2185-2188, 1989. (Pubitemid 19057691)
21. Wei Y, Lukashev M, Simon D, et al: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996. (Pubitemid 26301666)
22. Stahl A and Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 71: 116-122, 1997. (Pubitemid 27158418)
23. Dickinson JL, Bates EJ, Ferrante A and Antalis TM: Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 270: 27894-27904, 1995.
24. Astedt B, Lindoff C and Lecander I: Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost 24: 431-435, 1998. (Pubitemid 28525432)
25. Boudreau N, Andrews C, Srebrow A, Ravanpay A and Cheresh DA: Induction of the angiogenic phenotype by Hox D3. J Cell Biol 139: 257-264, 1997. (Pubitemid 27444096)
26. Nakamura M, Yang Q, Ozaki T, Nakamura Y, Yamasaki H, Mori I and Kakudo K: Induction of uPA but not NF-IL3A by calcitonin is dependent on Erk1/2 phosphorylation in porcine renal cell line LLC-PK1. Biochem Biophys Res Commun 290: 1483-1488, 2002. (Pubitemid 34687425)
27. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE and De Kier Joffe EB: Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263: 295-304, 1999. (Pubitemid 29337018)
28. Nguyen DH, Hussaini IM and Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502-8507, 1998. (Pubitemid 28168915)
29. Ma Z, Webb DJ, Jo M and Gonias SL: Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114: 3387-3396, 2001. (Pubitemid 33009262)
30. Jankun J, Merrick HW and Goldblatt PJ: Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53: 135-144, 1993. (Pubitemid 23294599)
31. Costantini V, Sidoni A, Dveglia R, Cazzato OA, Fem I, Bucciarelli E and Nenci GG: Combined overexpression of urokinase, urokinase receptor and plasminogen activator inhibitor-1 is associated with breast cancer progression. An immunohistochemical comparison of normal, benign and malignant breast tissues. Cancer 77: 1079-1088, 1996.
32. Dublin E, Hanby A, Patel NK, Liebman R and Barnes D: Immunohistochemical expression of uPA, uPAR and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol 157: 1219-1227, 2000.
33. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA and Choong PF: Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 61: 1-12, 2000. (Pubitemid 30440545)
34. Pyke C, Graem N, Ralfkiaer N, Hoeyer-Hansen G, Brunner N and Dano K: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993. (Pubitemid 23127124)
35. Bianchi E, Cohen RL, Thor AT, et al: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866, 1994. (Pubitemid 24085428)
36. Hildenbrand R, Leitz M and Magdolen V: Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in situ hybridization. Histopathology 36: 499-504, 2000. (Pubitemid 30348774)
37. Guyton DP, Evans DM and Sloan-Stakleff KD: Urokinase plasminogen activator receptor (uPAR): a potential indicator of invasion for in situ breast cancer. Breast J 6: 130-136, 2000. (Pubitemid 30227092)
38. Hildenbrand R and Arens N: Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br J Cancer 91: 564-571, 2004. (Pubitemid 39093580)
39. Zhao H, Morimoto T, Sasa M, Tanaka T and Izumi K: Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. Breast Cancer 9: 118-126, 2002.
40. Del Vecchio S, Stoppelli MP, Carriero MV, et al: Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198-3206, 1993. (Pubitemid 23210335)
41. Damjanovich L, Turzo C and Adany R: Factors involved in the plasminogen activation system in human breast tumours. Thromb Haemost 71: 684-691, 1994. (Pubitemid 24177952)
42. Nielsen BS, Sehested M, Duun S, et al: Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 81: 1485-1501, 2001. (Pubitemid 33064275)
43. Visscher DW, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S and Crissman JD: Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Mod Pathol 6: 302-306, 1993.
44. Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R and Kramer MD: Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer 77: 1638-1641, 1998. (Pubitemid 28230465)
45. Carriero MV, Franco P, Del Vecchio S, et al: Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454, 1994. (Pubitemid 24336039)
46. Escot C, Zhao Y, Puech C and Rochefort H: Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3 and urokinase plasminogen activator RNAs in breast cancer. Breast Cancer Res Treat 38: 217-226, 1996. (Pubitemid 26102149)
47. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G and Blanchette C: Expression of cathepsin D, stromelysin-3 and urokinase by reactive stromal cells on breast carcinoma prognosis. Cancer 92: 2957-2964, 2001.
48. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y and Takada A: Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb Res 63: 59-71, 1991.
49. Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA and Smith HS: Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60: 597-603, 1995.
50. Offersen BV, Nielsen BS, Hoyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J and Andreasen PA: The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 163: 1887-1899, 2003. (Pubitemid 37310019)
51. Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK and Andersen JA: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452, 1996.
52. Yang Q, Nakamura M, Nakamura Y, et al: Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res 22: 1825-1828, 2002. (Pubitemid 34839203)
53. Yang Q, Barbareschi M, Mori I, et al: Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 97: 512-517,2002. (Pubitemid 34027812)
54. Yang Q, Yoshimura G, Suzuma T, et al: Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 7: 3869-3873, 2001. (Pubitemid 34044603)
55. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer 62: 531-533, 1988.
56. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10: 39-49, 2004.
57. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F and Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
58. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74: 2276-2280, 1994. (Pubitemid 24322282)
59. Harbeck N, Dettmar P, Thomssen C, et al: Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80: 419-426, 1999. (Pubitemid 29213195)
60. Foekens JA, Peters HA, Look MP, et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 2000. (Pubitemid 30094561)
61. Janicke F, Prechtl A, Thomssen C, et al: German NO Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920, 2001. (Pubitemid 32624648)
62. Harbeck N, Kates RE and Schmitt M: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000-1007, 2002. (Pubitemid 34141844)
63. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993. (Pubitemid 23168015)
64. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F and Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994. (Pubitemid 24245001)
65. Grondahl-Hansen J, Christensen IJ, Briand P, et al: Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3: 233-239, 1997. (Pubitemid 27107300)
66. Loskutoff DJ, Curriden SA, Hu G and Deng G: Regulation of cell adhesion by PAI-1. APMIS 107: 54-61, 1999. (Pubitemid 29133523)
67. Bajou K, Masson V, Gerard RD, et al: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for anti-angiogenic strategies. J Cell Biol 152: 777-784, 2001. (Pubitemid 34280162)
68. Duggan C, Kennedy S, Kramer MD, et al: Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76: 622-627, 1997. (Pubitemid 27354676)
69. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG and Foekens JA: Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 68: 249-260, 2001. (Pubitemid 33702320)
70. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ and Duffy MJ.: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600, 1995.
71. Grondahl-Hansen J, Peters HA, van Putten WL, et al: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
72. Berger DH: Plasmin/plasminogen system in colorectal cancer. World J Surg 26: 767-771, 2002.
73. Ferno M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analyzed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
74. Grondahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brunner N: Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163, 1997. (Pubitemid 27165876)
75. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H and Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995.
76. Meijer-van Gelder ME, Look MP, Peters HA, et al: Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 64: 4563-4568, 2004. (Pubitemid 38856929)
77. Mangel WF, Toledo DL, Nardulli AM, Reiner GC, Norman MJ and Katzenellenbogen BS: Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem 30: 79-88, 1988.
78. Long BJ and Rose DP: Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells and a transfectant (S30) stably expressing ER. Cancer Lett 99: 209-215, 1996. (Pubitemid 26034636)
79. Levenson AS, Kwaan HC, Svoboda KM, Weiss IM, Sakurai S and Jordan VC: Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 78: 88-95, 1998. (Pubitemid 28276775)
80. Lin VC, Eng AS, Hen NE, Ng EH and Chowdhury SH: Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin Cancer Res 7: 2880-2886, 2001. (Pubitemid 32911398)
81. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival wih amplication on HER-2/neu oncogen. Science 235: 177-182, 1987. (Pubitemid 17231334)
82. Di Leo A, Larsimont D, Gancberg D, et al: HER-2 and topoisomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12: 1081-1089, 2001. (Pubitemid 32834488)
83. Andrulis IL, Bull SB, Blackstein ME, et al: Heu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340-1349, 1998. (Pubitemid 28175749)
84. Berney CR, Yang J, Fisher RJ, Russell PJ and Crowe PJ: Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 10: 47-54, 1998. (Pubitemid 128740429)
85. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000. (Pubitemid 30350211)
86. Harbeck N, Ross J, Yurdseven S, et al: HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol 14: 663-671, 1999.
87. Zemzoum I, Kates RE, Ross JS, et al: Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 21: 1022-1028, 2003.
88. Konecny G, Untch M, Arboleda J, et al: HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 7: 2448-2457, 2001. (Pubitemid 32751648)
89. Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol 71: 479-500, 1999.
90. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002. (Pubitemid 34233743)
91. Witowsky J, Abell A, Johnson NL, Johnson GL and Cuevas BD: MEKK1 is required for inducible urokinase-type plasminogen activator expression. J Biol Chem 278: 5941-5946, 2003. (Pubitemid 36800841)
92. Huang S, New L, Pan Z, Han J and Nemerow GR: Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 275: 12266-12272, 2000. (Pubitemid 30237807)
93. Seddighzadeh M, Zhou JN, Kronenwett U, et al: ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 17: 649-654, 1999. (Pubitemid 30450186)